Leukemia, Myelodysplasia, Transplantation
The drug is indicated for patients with CLL or SLL, with or without 17p deletion, who have had at least one prior therapy.
CHICAGO – The drug combination was evaluated in a phase 2 study of patients with previously untreated CLL.
CHICAGO – The study sheds light on the value of transplant after treatment with CAR T cells.
More than 8 in 10 youth were still alive and free of disease 4 years after starting combinations of methotrexate and/or nelarabine with chemo.
From the Journals
The long-term findings don’t raise red flags about safety with the drug in CLL.